Last updated on December 2019

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hepatitis C virus | Hepatitis C
  • Age: Between 18 - 99 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Participants are treatment-nave or treatment-experienced with pegylatedinterferon (pegIFN), or IFN, and/or ribavirin (RBV) and/or sofosbuvir (PRS) with confirmed chronic hepatitis C (CHC), genotypes 1, 2, 3, 4, 5, or 6, with or without compensated cirrhosis, receiving combination therapy with the all oral glecaprevir plus pibrentasvir (GLE/PIB) regimen according to standard of care, international guidelines and in line with the current local label.
  • Participants may be enrolled up to 4 weeks after treatment initiation
  • Participants must not be participating or intending to participate in a concurrent interventional therapeutic trial.

Exclusion Criteria:

  • None.

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.